BIIB · NASDAQ · STOCK
Biogen (BIIB) Stock Analysis
$225.69
52W $138.00 – $230.49
58/100
$33.35B
39.7
0.17
Is BIIB Bullish or Bearish?
Bullish.
Innellis AI committee rates Biogen (BIIB) Buy with a composite score of 58/100
, based on 5 analysts with 60% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +17.22 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -2.78 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.29 across 14 articles, 14d). Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- News sentiment is positive (+0.29 across 14 articles, 14d) — News
Bear Case
- P/E of 39.4 is moderate-to-rich — Value
- ROE of only 4.5% -- cheap may mean cheap for a reason — Value
- EPS declining -46.0% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
58/100
Agreement
60%
Analysts
5
Conviction
Moderate
Sector Rank
Top 47%
of 192 Healthcare peers
Value Analyst
neutral
55
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ Price-to-book of 1.4x is a discount to asset value
− P/E of 39.4 is moderate-to-rich
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -46.0% YoY despite any revenue growth
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
67
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.29 across 14 articles, 14d)
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 58.2 to 57.8.
- New bearish signals: 1 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- News Analyst: +1 bullish signal(s).
- Value Analyst: +1 bearish signal(s).
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
57.8
Neutral
MACD Histogram
-0.581
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$223.37
Resistance
$237.44
Bollinger %B
0.69
Inside Bands
Price vs Moving Averages
EMA 9
$222.93
Above
EMA 21
$221.88
Above
EMA 50
$217.24
Above
EMA 200
$197.34
Above
Fundamental Analysis
Valuation
66
Growth
55
Profitability
55
Financial Health
94
Cash Flow
70
Valuation
P/E Ratio
39.7×
P/B Ratio
1.77×
PEG Ratio
-0.87
Dividend Yield
0.00%
52W High
$230.49
52W Low
$138.00
Quality & Growth
ROE
708.4%
ROA
439.3%
Gross Margin
6770.7%
Operating Margin
1279.0%
Revenue Growth YoY
—
Debt / Equity
0.44
AI Fundamental Assessment
P/E ratio of 39.7 (rich relative to a 15-40x range); Price-to-book of 1.8x; PEG ratio of -0.9 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 7.1%; Return on assets of 4.4%; Net margin of 8.4%; Gross margin of 67.7%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.44; Free cash flow per share is positive (20.10); Most recent quarter beat estimates by 19.8%; 5 consecutive earnings beats; EPS growth decelerating (+79.4% -> +0.8% QoQ); Average YoY EPS growth of -34.2%; Analyst estimates rising over recent quarters
Get the Full BIIB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →